Logo
x

Search

Subscribe Now

Alzheimer disease

GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease

GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease

  • April 23, 2024
Genentech's Gantenerumab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

Genentech's Gantenerumab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

  • October 11, 2021
Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

  • June 30, 2021
Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

  • June 25, 2021
Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease

Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease

  • June 24, 2021
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

  • June 17, 2021
Lilly

    Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease

    • June 25, 2021
    Eisai and Biogen Receive FDA

      Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease

      • June 24, 2021
      Biogen

        Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

        • June 17, 2021
        Biogen and Eisai

          Biogen and Eisai's Aduhelm (aducanumab-avwa) Receive the US FDA's Accelerated Approval for Alzheimer Disease

          • June 8, 2021
          AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

            AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment d...

            • April 22, 2021
            LEXEO Therapeutics Receives the US FDA

              LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

              • April 21, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.